SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins selloff amid concerns over a reported Binance security breach is weighing on Strategy shares, with traders debating whether the crypto-market shock signals deeper trouble or a buying opportunity. Concerns about Strategys quarterly results and CFO transition add to the bearish discussion, while some investors expect a rebound.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths Medicare add-on reimbursement could decline sharply after the first quarter of 2027 has fueled concern about pricing and CorMedixs largest revenue driver, alongside a steep selloff. Traders disagree on whether the comments signal a lasting revenue threat or are preliminary, DaVita-specific estimates with limited visibility into future reimbursement and utilization.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has reached fresh 52-week highs, with traders focused on an expected Q3 earnings report and debating whether the rally reflects BRIUMVI growth expectations or speculative buyout hopes and short covering. The buyout talk remains unconfirmed, and the earnings date has not been officially confirmed.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak Q1 results, sharply reduced full-year outlook and dividend suspension have driven attention, as the company cited recession-level appliance demand and blamed the Iran war and collapsing consumer confidence. Many traders are alarmed by the worsening outlook and debt burden, while some see the selloff as an overreaction and are buying for a possible rebound.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

Weaker 2027 Medicare Advantage star ratings for Aetna are driving concern about lost bonus payments and future margin pressure. Traders are comparing CVSs weakness with Humanas rally on improved ratings, while debating whether the setback is already priced in.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Traders are focused on a possible update on Corvuss ALPS program around the ASH abstract release and a company call, though the timing and whether the data will be disclosed remain uncertain. Optimism about a potential catalyst is countered by concerns over past delays, managements limited updates and heavy short interest.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

RASONQUE (daraxonrasib), Revolution Medicines pancreatic cancer therapy, remains the main focus: traders cite its Phase 3 survival results and FDA approval as support for the companys commercial and broader RAS-drug pipeline prospects. Discussion is also divided over valuation and efficacy across KRAS subtypes, with some traders pointing to competition from selective G12D drugs such as Verastems VS-7375.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances updated NSCLC trial results and shift toward biomarker-selected lung-cancer studies are driving attention: the overall response rate was 24.6%, while a retrospective subgroup showed a stronger signal, but the lung-cancer filing is expected in 2027 and durability remains uncertain. Traders are divided between viewing the selloff as an overreaction to promising precision-treatment data and seeing a narrower, delayed opportunity compounded by managements confusing presentation.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples fiscal fourth-quarter earnings report is the focus, with traders debating whether its premium valuation can be justified amid memory-cost pressures and concerns about iPhone demand and upgrade cycles. Some expect a sharp post-report drop, while others view Apples restrained AI spending and relative resilience during the tech selloff as supporting its safe-haven appeal.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Arrowheads interim ARO-MAPT resultsshowing substantial tau reduction and supporting subcutaneous delivery of RNAi to the central nervous systemare a major focus. Traders broadly view the data as encouraging platform validation, but many are frustrated that the share price has not reflected the positive results and debate whether the weakness is market-driven or a sell-the-news reaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Natera, Shake Shack, eBay And More On CNBC's 'Final Trades'

CNBC Final Trades: Sechan picked eBay, Simpson Natera, Thomas COWZ ETF and Brown Shake Shack; all four gained Thursday.read more...

CareDx (CDNA) Surpasses Q3 Earnings and Revenue Estimates

CareDx (CDNA) delivered earnings and revenue surprises of +191.67% and +13.90%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Natera (NTRA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Natera (NTRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Natera to Report its Third Quarter Results on November 5, 2026

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its third quarter ended September 30, 2026, after the market closes on November 5, 2026. Natera will host a conference call and webcast shortly thereafter at 4:30...

NTRA Q3 Earnings on Deck: Will Signatera Volume Growth Drive Results?

Natera's third-quarter 2026 results hinge on Signatera volume growth, regulatory milestones and higher test prices, while expanding Medicare coverage may boost organ health revenues.

Signatera Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided a summary of key findings from the European Society for Medical Oncology (ESMO) Congress 2026. Following the presentation of several late-breaking datasets over the weekend, Nateras technology was...

Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data that was recently presented at the American Society of Nephrology (ASN) Kidney Week 2026, highlighting the unique value genetic testing can provide for patients with CKD. These 18...

Stanley Druckenmiller Has Bet Big on This 1 Healthcare Stock. Here's Why I Disagree.

Key PointsDruckenmiller owns a large stake in Natera...

Natera Partners With TransCode to Advance Colorectal Cancer Trial

NTRA partners with TransCode Therapeutics to use Signatera MRD testing in a Phase 2a colorectal cancer trial, aiming to accelerate enrollment and research.

ESMO 2026 Presentations Deepen the Evidence Base for Nateras Oncology Portfolio and Leadership in Ultrasensitive MRD Technology

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts featuring its technology will be presented at the 2026 European Society for Medical Oncology (ESMO) Annual Congress, taking place October 2326 in Madrid, Spain.New evidence...

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Natera Inc

NTRA Stock Hits All-Time High, OMER Stock Scales 5-Year Peak – What’s Driving Investors’ Enthusiasm Today?

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Natera expects to commercially launch the test in Japan in the first half of 2027</li><li>Cantor sees Yartemlea potentially capturing 30% to 40% of its market over time.</li><li>Yartemlea generated $28.5 million in second-quarter net sales, nearly triple its first-quarter sales.</li></ul>Shares of Natera (NTRA) and Omeros (OMER) surged on Tuesday, hitting key milestones, after Natera secured regulatory approval in Japan for its cancer test and Cantor Fitzgerald upgraded Omeros amid growing optimism about its lead drug’s commercial potential.At the time of writing, <a href="https://stocktwits.com/symbol/OMER">OMER shares</a> were up 12% to their highest levels since March 2021, while <a href="https://stocktwits.com/symbol/NTRA">NTRA shares</a> climbed 5% to a record high.<h2 class="st-heading-2">Natera’s Cancer Test Receives Japanese Approval</h2>Natera said on Tuesday that its Signatera cancer test received regulatory approval in Japan as a companion diagnostic for patients with muscle-invasive bladder cancer. A companion diagnostic is a test approved for use with a particular treatment to help identify patients who may benefit from that treatment.In this case, the approval allows Signatera to help identify patients who may benefit from treatment with Roche’s Tecentriq immunotherapy after surgery.Natera expects to commercially launch the test in Japan in the first half of 2027.The approval came from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), the country’s regulator for drugs and medical devices. It marks Signatera’s second regulatory approval in Japan, following an approval as a companion diagnostic for colorectal cancer in June. Signatera has also been approved by the U.S. Food and Drug Administration (FDA) as a companion diagnostic in muscle-invasive bladder cancer.Retail sentiment surrounding NTRA on Stocktwits remained ‘bearish’ over the past 24 hours. NTRA shares have gained more than 70% year-to-date.<h2 class="st-heading-2">Cantor Sees Peak Sales Of $400M For Omeros’ Lead Candidate</h2>Omeros received an upgrade from Cantor Fitzgerald on Tuesday over optimism around its key drug, Yartemlea.According to The Fly, Cantor upgraded Omeros to ‘Overweight’ from ‘Neutral’ with a $22 price target. After speaking with physicians, the firm said it is “increasingly convinced” that the drug could become larger than previously expected, with the potential to capture 30% to 40% of its market. Cantor raised its peak sales estimate to $400 million.Yartemlea treats TA-TMA, a serious complication that can occur after stem-cell transplants. The FDA approved it in December 2025 as the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-treat-serious-complication-stem-cell-transplant">first treatment</a> specifically approved for the condition.The drug generated $28.5 million in net sales in the second quarter, compared to $9.9 million in the first quarter.Retail sentiment surrounding OMER on Stocktwits turned to ‘neutral’ from ‘bearish’ over the past 24 hours, amid ‘high’ message volumes. The stock has gained more than 26% so far in 2026.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/cldx-stock-slumps-analyst-calls-phase-3-trial-safety-concerns-misplaced/cZMPHbZRB72">CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trending stock. (Photo Courtesy of Flavio Coelho via Getty Images)

Natera’s Signatera test secured a key regulatory approval, while Cantor raised its sales expectations for Omeros’ lead drug, Yartemlea.

Omeros Corp

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

NTRA News